Pure Precision:
Protein Innovation
for Life Sciences
Navigo Proteins® is a growing, innovative biotech company rooted in a long tradition of family entrepreneurs in Germany.
Through its core subsidiaries –Navigo Pure and Navigo Precision– along with its specialized asset vehicles, Navigo Proteins®, supports and builds sustainable innovation across the biotech landscape.
Core-Subsidiaries
Redefining downstream
processing with
Precision Capturing®
Navigo Pure drives innovation in affinity chromatography, delivering efficient, scalable, and sustainable bioprocessing solutions for the biotherapeutics industry.
Pioneering the
Next Generation of
Targeted Therapies
Navigo Precision enhances patient diagnosis, treatment, and quality of life by developing innovative products for diseases with significant unmet medical needs.
Asset Vehicles
Navigo Proteins has licensed its technology to GAIASO Theranostics and OptigoBio. Both companies bring strong expertise in their respective fields and were established to efficiently advance promising assets into clinical development.
We refer to these independent companies as “Asset Vehicles”, as they were founded with the support and partial ownership of Navigo Proteins®. This structure allows for the integration of deep clinical and medical expertise, streamlined decision-making, and the flexibility to form new strategic partnerships while maintaining focused development pathways.
Our Asset Vehicles
GAIASO is developing radiotheranostic products in one of the fastest-growing areas of oncology, female cancers—an especially challenging field where innovative treatment options remain scarce.
OptigoBio is developing cutting-edge treatments for vision loss caused by chronic ophthalmic diseases, led by an expert team advancing next-generation intravitreal therapies.
Let’s connect
If you have questions, want to inquire about a collaboration or product, simply leave us a message. We’ll get back to you as soon as possible.
"*" indicates required fields